Premium
Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases
Author(s) -
Zillikens Detlef,
Derfler Kurt,
Eming Rüdiger,
Fierlbeck Gerhard,
Goebeler Matthias,
Hertl Michael,
Hofmann Silke C.,
Karlhofer Franz,
Kautz Ocko,
Nitschke Martin,
Opitz Andreas,
Quist Sven,
Rose Christian,
Schanz Stefan,
Schmidt Enno,
Shimanovich Iakov,
Michael Michael,
Ziller Fabian
Publication year - 2007
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/j.1610-0387.2007.06342.x
Subject(s) - medicine , bullous pemphigoid , autoimmune disease , dermatology , disease , pemphigoid , intensive care medicine , immunology , antibody
Summary Despite the use of high‐dose systemic corticosteroids in combination with other immunosuppressants, in some patients with autoimmune bullous diseases only insufficient improvement is achieved. In these cases and in acute severe disease, adjuvant immunoapheresis has been increasingly used. A consensus meeting was held in mid‐2005 in Hamburg, aiming at developing guidelines for the use of immunoapheresis in the treatment of autoimmune bullous diseases.This paper summarizes the experts‘ recommendations.